DiaMedica Therapeutics (DMAC) Non-Current Assets (2017 - 2026)

DiaMedica Therapeutics (DMAC) has reported Non-Current Assets for 10 consecutive years, with $686000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets rose 75.45% year-over-year to $686000.0; the trailing twelve-month figure through Jun 2026 stood at $686000.0 (up 75.45% YoY), and the FY2025 full-year result was $742000.0, down 57.23% from the prior year.
• Non-Current Assets declined to $686000.0 in Q2 2026 per DMAC's latest filing, from $717000.0 in the prior quarter.
• Across five years, Non-Current Assets topped out at $20.8 million in Q2 2023 and bottomed at $85000.0 in Q2 2022.
• Historically, Non-Current Assets has averaged $2.5 million across 5 years, with a median of $729500.0 in 2025.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets jumped 24392.94% in 2023, then tumbled 91.46% in 2024.
• Over 5 years, Non-Current Assets stood at $560000.0 in 2022, then retreated by 13.39% to $485000.0 in 2023, then jumped by 257.73% to $1.7 million in 2024, then plunged by 57.23% to $742000.0 in 2025, then retreated by 7.55% to $686000.0 in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $686000.0, $717000.0, and $742000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.